5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluation of Mannose Binding Lectin Gene Variants in Pediatric Influenza Virus-Related Critical Illness

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Mannose-binding lectin (MBL) is an innate immune protein with strong biologic plausibility for protecting against influenza virus-related sepsis and bacterial co-infection. In an autopsy cohort of 105 influenza-infected young people, carriage of the deleterious MBL gene MBL2_Gly54Asp(“B”) mutation was identified in 5 of 8 individuals that died from influenza-methicillin-resistant Staphylococcus aureus (MRSA) co-infection. We evaluated MBL2 variants known to influence MBL levels with pediatric influenza-related critical illness susceptibility and/or severity including with bacterial co-infections.

          Methods: We enrolled children and adolescents with laboratory-confirmed influenza infection across 38 pediatric intensive care units from November 2008 to June 2016. We sequenced MBL2 “low-producer” variants rs11003125(“H/L”), rs7096206(“Y/X”), rs1800450 Gly54Asp(“B”), rs1800451 Gly57Glu(“C”), rs5030737 Arg52Cys(“D”) in patients and biologic parents. We measured serum levels and compared complement activity in low-producing homozygotes (“B/B,” “C/C”) to HYA/HYA controls. We used a population control of 1,142 healthy children and also analyzed family trios (PBAT/HBAT) to evaluate disease susceptibility, and nested case-control analyses to evaluate severity.

          Results: We genotyped 420 patients with confirmed influenza-related sepsis: 159 (38%) had acute lung injury (ALI), 165 (39%) septic shock, and 30 (7%) died. Although bacterial co-infection was diagnosed in 133 patients (32%), only MRSA co-infection ( n = 33, 8% overall) was associated with death ( p < 0.0001), present in 11 of 30 children that died (37%). MBL2 variants predicted serum levels and complement activation as expected. We found no association between influenza-related critical illness susceptibility and MBL2 variants using family trios (633 biologic parents) or compared to population controls. MBL2 variants were not associated with admission illness severity, septic shock, ALI, or bacterial co-infection diagnosis. Carriage of low-MBL producing MBL2 variants was not a risk factor for mortality, but children that died did have higher carriage of one or more B alleles (OR 2.3; p = 0.007), including 7 of 11 with influenza MRSA-related death (vs. 2 of 22 survivors: OR 14.5, p = 0.0002).

          Conclusions: MBL2 variants that decrease MBL levels were not associated with susceptibility to pediatric influenza-related critical illness or with multiple measures of critical illness severity. We confirmed a prior report of higher B allele carriage in a relatively small number of young individuals with influenza-MRSA associated death.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Implementing a unified approach to family-based tests of association.

          We describe a broad class of family-based association tests that are adjusted for admixture; use either dichotomous or measured phenotypes; accommodate phenotype-unknown subjects; use nuclear families, sibships or a combination of the two, permit multiple nuclear families from a single pedigree; incorporate di- or multi-allelic marker data; allow additive, dominant or recessive models; and permit adjustment for covariates and gene-by-environment interactions. The test statistic is basically the covariance between a user-specified function of the genotype and a user-specified function of the trait. The distribution of the statistic is computed using the appropriate conditional distribution of offspring genotypes that adjusts for admixture.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans

            Previous studies reported associations of IFITM3 SNP rs12252 with severe influenza, but evidence of association and the mechanism of risk remains controversial. We prioritized SNPs in IFITM3 based on putative biological function and identified rs34481144 in the 5′ UTR. We found evidence of a novel association of rs34481144 with severe influenza in three influenza-infected cohorts characterized by different levels of influenza illness severity. We determined the role of rs34481144 as an expression quantitative trait loci (eQTL) for IFITM3 , with the risk allele associated with lower mRNA expression. The risk allele was found to have decreased IRF3 binding and increased CTCF binding in promoter-binding assays, and risk allele carriage diminished transcriptional correlations among neighboring genes, indicative of CTCF boundary activity. Furthermore, the risk allele disrupts a CpG site that undergoes differential methylation in CD8 T-cell subsets. Carriers of the risk allele had reduced CD8 T-cells in their airways during natural influenza infection, consistent with IFITM3 promoting airway CD8 T-cell accumulation, indicating that a critical function for IFITM3 may be to promote immune cell persistence at mucosal sites. Our study identifies a new regulator of IFITM3 expression that associates with CD8 T-cell levels in the airways and a spectrum of clinical outcomes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Critically ill children during the 2009-2010 influenza pandemic in the United States.

              The 2009 pandemic influenza A (H1N1) (pH1N1) virus continues to circulate worldwide. Determining the roles of chronic conditions and bacterial coinfection in mortality is difficult because of the limited data for children with pH1N1-related critical illness. We identified children (<21 years old) with confirmed or probable pH1N1 admitted to 35 US PICUs from April 15, 2009, through April 15, 2010. We collected data on demographics, baseline health, laboratory results, treatments, and outcomes. Of 838 children with pH1N1 admitted to a PICU, the median age was 6 years, 58% were male, 70% had ≥1 chronic health condition, and 88.2% received oseltamivir (5.8% started before PICU admission). Most patients had respiratory failure with 564 (67.3%) receiving mechanical ventilation; 162 (19.3%) received vasopressors, and 75 (8.9%) died. Overall, 71 (8.5%) of the patients had a presumed diagnosis of early (within 72 hours after PICU admission) Staphylococcus aureus coinfection of the lung with 48% methicillin-resistant S aureus (MRSA). In multivariable analyses, preexisting neurologic conditions or immunosuppression, encephalitis (1.7% of cases), myocarditis (1.4% of cases), early presumed MRSA lung coinfection, and female gender were mortality risk factors. Among 251 previously healthy children, only early presumed MRSA coinfection of the lung (relative risk: 8 [95% confidence interval: 3.1-20.6]; P < .0001) remained a mortality risk factor. Children with preexisting neurologic conditions and immune compromise were at increased risk of pH1N1-associated death after PICU admission. Secondary complications of pH1N1, including myocarditis, encephalitis, and clinical diagnosis of early presumed MRSA coinfection of the lung, were mortality risk factors.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                08 May 2019
                2019
                : 10
                : 1005
                Affiliations
                [1] 1Division of Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital and Department of Anaesthesia, Harvard Medical School , Boston, MA, United States
                [2] 2Divisions of Pediatric Critical Care and Pediatric Infectious Diseases, Department of Pediatrics, Mayo Clinic , Rochester, MN, United States
                [3] 3Foundation Medicine Inc. , Cambridge, MA, United States
                [4] 4Wyss Institute at Harvard University , Boston, MA, United States
                [5] 5Influenza Division, US Centers for Disease Control and Prevention , Atlanta, GA, United States
                [6] 6Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, MD, United States
                [7] 7Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Miami Miller School of Medicine , Miami, FL, United States
                [8] 8Critical Care Medicine Division, Department of Pediatrics, Children's Hospital of Los Angeles, University of California, Los Angeles , Los Angeles, CA, United States
                [9] 9Section of Critical Care Medicine, Department of Pediatrics, Texas Children's Hospital , Houston, TX, United States
                [10] 10Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia , Philadelphia, PA, United States
                [11] 11Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital , Columbus, OH, United States
                [12] 12Department of Pediatrics, Benioff Children's Hospital Oakland, University California San Francisco , Oakland, CA, United States
                [13] 13Department of Pediatrics, Children's Hospital of Orange County , Orange, CA, United States
                [14] 14Division of Pediatric Critical Care Medicine, Department of Pediatrics, Children's Healthcare of Atlanta at Egleston, Emory University School of Medicine , Atlanta, GA, United States
                [15] 15Section of Critical Care Medicine, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado , Aurora, CO, United States
                [16] 16Department of Pediatrics, Harvard Medical School , Boston, MA, United States
                Author notes

                Edited by: Luregn J. Schlapbach, University of Queensland, Australia

                Reviewed by: Michiel Van Der Flier, Radboud University Medical Center, Netherlands; Lachlan James Coin, University of Queensland, Australia

                *Correspondence: Adrienne G. Randolph adrienne.randolph@ 123456childrens.harvard.edu

                This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology

                †PALISI PICFLU Investigators are listed in the acknowledgments

                Article
                10.3389/fimmu.2019.01005
                6518443
                31139182
                0398db8d-45c2-457c-b757-1131e0cb22da
                Copyright © 2019 Levy, Yip, Super, Ferdinands, Mistry, Newhams, Zhang, Su, McLaughlin, Sapru, Loftis, Weiss, Hall, Cvijanovich, Schwarz, Tarquinio, Mourani, PALISI PICFLU Investigators and Randolph.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 28 August 2018
                : 18 April 2019
                Page count
                Figures: 4, Tables: 3, Equations: 0, References: 58, Pages: 12, Words: 8949
                Funding
                Funded by: National Institutes of Health 10.13039/100000002
                Funded by: Centers for Disease Control and Prevention 10.13039/100000030
                Categories
                Immunology
                Original Research

                Immunology
                mbl,influenza,pediatric,methicillin-resistant staphylococcus aureus,critical illness,sepsis,mortality

                Comments

                Comment on this article